Abstract
Circulating tumor cells (CTCs) have attracted interest as biomarkers of cancer metastases but only recently has a reliable method of CTC detection been developed. CTCs can be thought of as a liquid biopsy from the blood, and they can be used in pathological and molecular assays. CTCs may ideally replace metastatic tissue biopsies in the prediction and monitoring of therapeutic responses and tumor recurrence. CTCs can be used to guide therapeutic cancer management and serve as drug targets. For this reason, the potential of this technology and the limitations of currently available methods of CTC detection are addressed here. The clinical applications of CTCs include the prediction of cancer prognosis; selection and monitoring of therapeutic regimens; and drug target applications. The manner in which CTC molecular profiling can facilitate prognosis and the selection of cancer therapies.
Keywords: Circulating tumor cells, drug target, enrichment and detection, immunotherapy.
Current Drug Targets
Title:Circulating Tumor Cells (CTCs) as a Liquid Biopsy Material and Drug Target
Volume: 15 Issue: 10
Author(s): Liang-Liang Cai, Hui-Ming Ye, Li-Mou Zheng, Run-Sheng Ruan and Chi-Meng Tzeng
Affiliation:
Keywords: Circulating tumor cells, drug target, enrichment and detection, immunotherapy.
Abstract: Circulating tumor cells (CTCs) have attracted interest as biomarkers of cancer metastases but only recently has a reliable method of CTC detection been developed. CTCs can be thought of as a liquid biopsy from the blood, and they can be used in pathological and molecular assays. CTCs may ideally replace metastatic tissue biopsies in the prediction and monitoring of therapeutic responses and tumor recurrence. CTCs can be used to guide therapeutic cancer management and serve as drug targets. For this reason, the potential of this technology and the limitations of currently available methods of CTC detection are addressed here. The clinical applications of CTCs include the prediction of cancer prognosis; selection and monitoring of therapeutic regimens; and drug target applications. The manner in which CTC molecular profiling can facilitate prognosis and the selection of cancer therapies.
Export Options
About this article
Cite this article as:
Cai Liang-Liang, Ye Hui-Ming, Zheng Li-Mou, Ruan Run-Sheng and Tzeng Chi-Meng, Circulating Tumor Cells (CTCs) as a Liquid Biopsy Material and Drug Target, Current Drug Targets 2014; 15 (10) . https://dx.doi.org/10.2174/1389450115666140902125150
DOI https://dx.doi.org/10.2174/1389450115666140902125150 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mutations in MicroRNA Genes and Their Binding Sites are Infrequently Associated with Human Colorectal Cancer in the Kashmiri Population
MicroRNA Endoradiotherapy with Peptides - Status and Future Development
Current Medicinal Chemistry The Role of Clusterin in Carcinogenesis and its Potential Utility as Therapeutic Target
Current Medicinal Chemistry Oxidative Stress and Cellular Senescence: The Key Tumor-promoting Factors in Colon Cancer and Beneficial Effects of Polyphenols in Colon Cancer Prevention
Current Cancer Therapy Reviews Novel Biomarkers of microRNAs in Gastric Cancer: An Overview from Diagnosis to Treatment
MicroRNA Enrichment of Up-regulated and Down-regulated Gene Clusters Using Gene Ontology, miRNAs and lncRNAs in Colorectal Cancer
Combinatorial Chemistry & High Throughput Screening Small-molecule Inhibitors of Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinases (TK)
Current Pharmaceutical Design High Expression of MYL9 Indicates Poor Clinical Prognosis of Epithelial Ovarian Cancer
Recent Patents on Anti-Cancer Drug Discovery Choline Nutrition Programs Brain Development Via DNA and Histone Methylation
Central Nervous System Agents in Medicinal Chemistry Elucidation of PLK1 Linked Biomarkers in Oesophageal Cancer Cell Lines: A Step Towards Novel Signaling Pathways by p53 and PLK1-Linked Functions Crosstalk
Protein & Peptide Letters Cytostatic and Apoptotic Effects of DNMT and HDAC Inhibitors in Endometrial Cancer Cells
Current Pharmaceutical Design The Role of ING Tumor Suppressors in UV Stress Response and Melanoma Progression
Current Drug Targets Optimising the Azeotropic Drying of 18F-Fluorine Wayto Improve the 18F-Fluorocholine Radiochemical Yield
Current Radiopharmaceuticals The Role of Capecitabine in the Management of Tumors of the Digestive System
Reviews on Recent Clinical Trials The Role of Peptidyl Prolyl Isomerases in Aging and Vascular Diseases
Current Molecular Pharmacology MicroRNAs and Lung Cancer: New Oncogenes and Tumor Suppressors, New Prognostic Factors and Potential Therapeutic Targets
Current Medicinal Chemistry Protein Kinase B/AKT and Focal Adhesion Kinase: Two Close Signaling Partners in Cancer
Anti-Cancer Agents in Medicinal Chemistry Evolution and Pathogenesis of Oncoviruses Associated with Head and Neck Cancer: History and Current Concepts
Recent Patents on Biomarkers Unfoldomics of Human Genetic Diseases: Illustrative Examples of Ordered and Intrinsically Disordered Members of the Human Diseasome
Protein & Peptide Letters The Role of Target Therapy in the Treatment of Gastrointestinal Noncolorectal Cancers: Clinical Impact and Cost Consideration
Current Cancer Drug Targets